Clinical Trials Logo

Dry Eye Syndromes clinical trials

View clinical trials related to Dry Eye Syndromes.

Filter by:

NCT ID: NCT03693183 Withdrawn - Dry Eye Clinical Trials

Efficacy Study of Ketorolac and HPMC to Treat Dry Eye

Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether ketorolac and Hydroxypropyl Methylcellulose are effective in the treatment of Dry Eye.

NCT ID: NCT03431272 Withdrawn - Clinical trials for Contact Lens Dry Eye

Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

Start date: November 1, 2018
Phase: Phase 4
Study type: Interventional

Discomfort with contact lens wear is the biggest reason why people stop wearing contact lenses. The investigators believe that inflammation is one of the causes of discomfort, and by blocking the inflammation using lifitegrast, the investigators may be able to relieve some of that discomfort. This study will enroll 50 subjects with contact lens discomfort and will receive lifitegrast to use over a period of approximately 3 months.

NCT ID: NCT03408015 Withdrawn - Dry Eye Clinical Trials

Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease

Start date: January 2019
Phase: Phase 4
Study type: Interventional

Every night during sleep, there is an accumulation of white blood cells in the closed eye. The closed eye white blood cells are predominantly neutrophils, but there is a small population (3%) of T cells. The effects of these closed eye white blood cells on dry eye disease pathogenesis have yet to be fully elucidated, but preliminary evidence suggests that closed eye neutrophils may have an associated hyperactivity and increased degranulation in dry eye disease that could contribute to epithelial instability. As an anti-T cell therapy, Xiidra offers an opportunity to better understand how the closed eye white blood cells are recruited and activated. This study also seeks to verify the proposed mechanism of action.

NCT ID: NCT03398018 Withdrawn - Clinical trials for Keratoconjunctivitis Sicca

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

Start date: November 1, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this pilot study is to assess repository corticotropin injection (RCI) in the form of H.P. Acthar Gel in patients with severe keratoconjunctivitis sicca (KCS, or dry eye disease). This pilot study is a non-randomized, open-label, interventional study to assess the efficacy and timeline of RCI for the treatment of severe KCS recalcitrant to conventional therapy. The purpose is to acquire preliminary data to support and guide the design of a future, double-masked, randomized, controlled clinical trial.

NCT ID: NCT03396809 Withdrawn - Dry Eye Syndromes Clinical Trials

Punctal Plugs and Iodine Related Discomfort

Start date: July 26, 2017
Phase: N/A
Study type: Interventional

Purpose: Intravitreal injection of medications has revolutionized the treatment microvascular diseases. These diseases often require regular, life-long injections. Ensuring patient comfort is important for compliance with long-term treatments. Patients receiving regular intravitreal injections often complain of progressive dry eye related discomfort. These symptoms are likely secondary to the use of povidone iodine as an antiseptic. Investigators hypothesize that punctal plugs could reverse the progressive ocular surface discomfort induced by povidone iodine during the post-procedural state.

NCT ID: NCT03286166 Withdrawn - Dry Eye Clinical Trials

Single Center, Prospective, Randomized, Controlled, Non-significant Risk

Start date: December 1, 2021
Phase:
Study type: Observational

A randomized controlled trial to evaluate the efficiency of serum tears made with Genius PRP for improving signs and symptoms in Dry Eye Disease (DED). Single center, Prospective, Randomized, Controlled, Non-significant risk

NCT ID: NCT02028312 Withdrawn - Dry Eye Disease Clinical Trials

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

Start date: January 2014
Phase: Phase 4
Study type: Interventional

A pilot study to evaluate the impact of Lotemax® Gel (loteprednol etabonate ophthalmic gel 0.5%) on the initiation of Restasis® (cyclosporine ophthalmic emulsion 0.05%) therapy in subjects with dry eye.

NCT ID: NCT01957670 Withdrawn - Dry Eye Syndrome Clinical Trials

Pilot Study to Clinical Evaluate Device Prototypes in Dry Eye Patients

Start date: February 2014
Phase: N/A
Study type: Interventional

The study will assess the safety, tolerability and feasibility of Lacrima investigational medical device to treat dry eye patients

NCT ID: NCT01917539 Withdrawn - Dry Eye Syndrome Clinical Trials

Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome

Start date: June 2013
Phase: N/A
Study type: Interventional

Our primary aim is to determine whether pulsed light therapy (PLT) is effective in reducing symptoms and improving clinical stigmata of dry eye syndrome (DES) associated with meibomian gland dysfunction (MGD) in patients with facial rosacea (which includes ocular rosacea). The uses of PLT are for treatment of rosacea, hair removal, pigmented lesions, and skin telangiectasias. The risks include the potential for transient sunburn-like sensations (i.e. redness, burning sensation) and particularly if not used properly, the potential to cause burns, blistering, scarring, and pigmentary changes.

NCT ID: NCT01791426 Withdrawn - Dry Eye Clinical Trials

A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye

Start date: May 2013
Phase: N/A
Study type: Interventional

The objective of this investigation is to show that the performance of Artelac Rebalance eye drops is non-inferior to that of Vismed eye drops in subjects with moderate to severe dry eye, and to assess the safety of Artelac Rebalance after a 90-day (± 10 day) treatment administered 3 to 5 times per day.